A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome
Latest Information Update: 09 Dec 2024
Price :
$35 *
At a glance
- Drugs REGN-7544 (Primary)
- Indications Postural orthostatic tachycardia syndrome
- Focus Therapeutic Use
- Sponsors Regeneron Pharmaceuticals
- 22 Nov 2024 Status changed from not yet recruiting to recruiting.
- 23 Sep 2024 New trial record